Related Experiment Video
Updated: Jul 23, 2025

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
Published on: January 20, 2019
PARP1 Inhibition Halts EBV+ Lymphoma Progression by Disrupting the EBNA2/MYC Axis
Giorgia Napoletani1, Samantha S Soldan1, Toshitha Kannan1
1The Wistar Institute, Philadelphia, PA, 19104, USA.
Abstract:
PARP1 has been shown to regulate EBV latency. However, the therapeutic effect of PARP1 inhibitors on EBV+ lymphomagenesis has not yet been explored. Here, we show that PARPi BMN-673 has a potent anti-tumor effect on EBV-driven LCL in a mouse xenograft model. We found that PARP1 inhibition induces a dramatic transcriptional reprogramming of LCLs driven largely by the reduction of the MYC oncogene expression and dysregulation of MYC targets, both in vivo and in vitro. PARP1 inhibition also reduced the expression of viral oncoprotein EBNA2, which we previously demonstrated depends on PARP1 for activation of MYC. Further, we show that PARP1 inhibition blocks the chromatin association of MYC, EBNA2, and tumor suppressor p53. Overall, our study strengthens the central role of PARP1 in EBV malignant transformation and identifies the EBNA2/MYC pathway as a target of PARP1 inhibitors and its utility for the treatment of EBNA2-driven EBV-associated cancers.
Insights
PARP1 inhibitors show potent anti-tumor effects against Epstein-Barr virus (EBV)-driven lymphomas by targeting the EBNA2/MYC pathway. This research highlights a new therapeutic strategy for EBV-associated cancers.
Area of Science:
- Oncology
- Molecular Biology
- Virology
Background:
- Poly (ADP-ribose) polymerase 1 (PARP1) regulates Epstein-Barr virus (EBV) latency.
- The therapeutic potential of PARP1 inhibitors in EBV-associated lymphomagenesis remains unexplored.
Purpose of the Study:
- To investigate the anti-tumor effects of PARP1 inhibitors on EBV-driven lymphomas.
- To elucidate the molecular mechanisms underlying PARP1 inhibition in EBV-driven lymphomagenesis.
Main Methods:
- Utilized a mouse xenograft model of EBV-driven lymphoblastoid cells (LCLs).
- Assessed the effects of the PARP1 inhibitor BMN-673 on LCLs in vivo and in vitro.
- Analyzed transcriptional changes, oncogene expression (MYC), viral oncoprotein (EBNA2), and chromatin association of key proteins (MYC, EBNA2, p53).
Main Results:
- PARP1 inhibition demonstrated potent anti-tumor activity against EBV-driven LCLs.
- PARP1 inhibition led to significant transcriptional reprogramming, primarily through the downregulation of the MYC oncogene and its targets.
- Reduced expression of viral oncoprotein EBNA2 and blocked chromatin association of MYC, EBNA2, and p53.
Conclusions:
- PARP1 plays a critical role in EBV-driven malignant transformation.
- The EBNA2/MYC pathway is a key target for PARP1 inhibitors in EBV-associated cancers.
- PARP1 inhibitors represent a promising therapeutic strategy for EBNA2-driven EBV-associated malignancies.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
Restarting Stalled Replication Forks
Mitogens and the Cell Cycle
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
DNA Damage can Stall the Cell Cycle

